Navigating Health Policy: What Cancer Patients Should Know for 2027 image

Navigating Health Policy: What Cancer Patients Should Know for 2027

Can't make it to the event?
We send a recording to all registered participants of the event!
Dec 03, 2026
03:30PM - 04:30PM EST
Online Event
Overview

What could changes in healthcare policy mean for people living with cancer? Join HealthTree for a look back at the cancer policy landscape in 2026 and a preview of the issues that could shape cancer care in 2027. We’ll explore key developments affecting cancer patients, including access to care, affordability, and research, and discuss what patients and caregivers should know as we head into the new year. Whether you’re new to cancer advocacy or simply want to better understand how policy can affect your care, this conversation will help you stay informed and prepared.

Agenda
3:30 PM
Introduction
Hannah Loosle

Hannah introduces the agenda and our speaker Andrew Scott

3:35 PM
Presentation
Andres Chang, MD PhD

Andrew shares on health policy development for 2027

4:05 PM
Questions and Answers
Audience

Come with your questions and we will answer them! 

Speakers & Moderators
Healthtree contact Hannah Loosle

Hannah Loosle

Hannah joined HealthTree Foundation as the Lymphoma Education Manager in 2024. She is a Certified Health Education Specialist and is passionate about helping patients feel empowered through education and connection. Before joining HealthTree, Hannah worked in healthcare policy helping patients advocate for better care, research, and funding.
Healthtree contact Andrew Scott

Andrew Scott

Andrew Scott serves as a Senior Director, Alliance Development within Bristol Myers Squibb’s US Policy & Government Affairs in Washington, DC. Focusing on oncology, Andrew prioritizes mutual value creation, thinking of health systems holistically, and collaborating with diverse stakeholders to advance public policy that improves patient access and protects innovation. Before BMS, he served as Vice President of Policy & Public Affairs at Global Liver Institute (GLI), leading the organization’s efforts to elevate the patient voice, and shape public policy to address the unmet need of patients impacted by liver disease. Before GLI, he acted as Senior Federal Affairs Director at Cullari Communications Global, a public affairs advocacy firm, where he provided clients with advocacy campaign support at the state and federal level. He got his start in health policy and government affairs at Endo Pharmaceuticals, serving as the company’s principal federal lobbyist. Andrew received his Master of Business Administration from the University of North Carolina’s Kenan-Flagler Business School in 2022.